Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study.

Autor:	Magnúsdóttir I; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland., Lovik A; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Unnarsdóttir AB; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland., McCartney D; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK., Ask H; Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway., Kõiv K; Estonian Genome Centre, Institute of Genomics, University of Tartu, Estonia., Christoffersen LAN; Institute of Biological Psychiatry, Mental Health Services Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark., Johnson SU; Department of Psychology, University of Oslo, Oslo, Norway; Modum Bad Psychiatric Center, Vikersund, Norway., Hauksdóttir A; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland., Fawns-Ritchie C; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK; Department of Psychology, University of Edinburgh, Edinburgh, UK., Helenius D; Institute of Biological Psychiatry, Mental Health Services Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark., González-Hijón J; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Lu L; Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway; NORMENT Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Ebrahimi OV; Department of Psychology, University of Oslo, Oslo, Norway; Modum Bad Psychiatric Center, Vikersund, Norway., Hoffart A; Department of Psychology, University of Oslo, Oslo, Norway; Modum Bad Psychiatric Center, Vikersund, Norway., Porteous DJ; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK., Fang F; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Jakobsdóttir J; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland., Lehto K; Estonian Genome Centre, Institute of Genomics, University of Tartu, Estonia., Andreassen OA; NORMENT Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway., Pedersen OBV; Department of Clinical Immunology, Zealand University Hospital, Koege, Denmark., Aspelund T; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; The Icelandic Heart Association, Kopavogur, Iceland., Valdimarsdóttir UA; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA. Electronic address: unnurav@hi.is.
Jazyk:	angličtina
Zdroj:	The Lancet. Public health [Lancet Public Health] 2022 May; Vol. 7 (5), pp. e406-e416. Date of Electronic Publication: 2022 Mar 14.
DOI:	10.1016/S2468-2667(22)00042-1
Abstrakt:	Background: Long-term mental and physical health consequences of COVID-19 (long COVID) are a persistent public health concern. Little is still known about the long-term mental health of non-hospitalised patients with COVID-19 with varying illness severities. Our aim was to assess the prevalence of adverse mental health symptoms among individuals diagnosed with COVID-19 in the general population by acute infection severity up to 16 months after diagnosis. Methods: This observational follow-up study included seven prospectively planned cohorts across six countries (Denmark, Estonia, Iceland, Norway, Sweden, and the UK). Participants were recruited from March 27, 2020, to Aug 13, 2021. Individuals aged 18 years or older were eligible to participate. In a cross-sectional analysis, we contrasted symptom prevalence of depression, anxiety, COVID-19-related distress, and poor sleep quality (screened with validated mental health instruments) among individuals with and without a diagnosis of COVID-19 at entry, 0-16 months from diagnosis. In a cohort analysis, we further used repeated measures to estimate the change in mental health symptoms before and after COVID-19 diagnosis. Findings: The analytical cohort consisted of 247 249 individuals, 9979 (4·0%) of whom were diagnosed with COVID-19 during the study period. Mean follow-up was 5·65 months (SD 4·26). Participants diagnosed with COVID-19 presented overall with a higher prevalence of symptoms of depression (prevalence ratio [PR] 1·18 [95% CI 1·03-1·36]) and poorer sleep quality (1·13 [1·03-1·24]) but not symptoms of anxiety (0·97 [0·91-1·03]) or COVID-19-related distress (1·05 [0·93-1·20]) compared with individuals without a COVID-19 diagnosis. Although the prevalence of depression and COVID-19-related distress attenuated with time, individuals diagnosed with COVID-19 but never bedridden due to their illness were consistently at lower risk of depression (PR 0·83 [95% CI 0·75-0·91]) and anxiety (0·77 [0·63-0·94]) than those not diagnosed with COVID-19, whereas patients who were bedridden for more than 7 days were persistently at higher risk of symptoms of depression (PR 1·61 [95% CI 1·27-2·05]) and anxiety (1·43 [1·26-1·63]) than those not diagnosed throughout the study period. Interpretation: Severe acute COVID-19 illness-indicated by extended time bedridden-is associated with long-term mental morbidity among recovering individuals in the general population. These findings call for increased vigilance of adverse mental health development among patients with a severe acute disease phase of COVID-19. Funding: Nordforsk, Horizon2020, Wellcome Trust, and Estonian Research Council. Competing Interests: Declaration of interests OAA has received a grant to their institution from Nordforsk and Research Council of Norway for the present manuscript. OAA has also received a grant to the institution for an entity other than the present manuscript from South East Norway Health Authority, KG Jebsen Stiftelsen, and National Institutes of Health, EU. OAA has received royalties for a textbook in psychiatry, consulting fees from HealthLytix and Milken Institute, payment for lectures from Sunovion and Lundbeck, and payment for expert testimony from the Norwegian Court. Outside of this work, OAA has a patent for a devise for nasal delivery. OAA has participated at his institution on boards for local principal investigator Clinical Trial Janssen, local principal investigator Clinical Trial MAPS, and local principal investigator Clinical Trial Boehringer. UAV has received grants for the current work from Nordforsk and Horizon2020 as well as grants outside the current work from the Icelandic Research Fund, Swedish Research Council, Swedish Cancer Society, and the European Research Council. All other authors declare no competing interests. (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu